0
Upcoming Allied Market Research
2023
Digital Dose Inhaler Market

Digital Dose Inhaler Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

Report Code: A10384
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Digital Dose Inhaler Market

Request Now !

Inhalers are also named as allergy spray or pump. Inhalers are mostly used for treatment and medication delivery for respiratory diseases including chronic obstructive pulmonary disease and asthma. Inhalers play a vital role in the management of patients with obstructive airway disease (OAD). Inhalers minimize medication in throat or mouth and the need for exact synchronization with actuation of the device. The digital inhaler is a device that delivers a specific amount of medication to the lungs, in the form of a short burst of aerosolized medicine that is self-administered by the patient through inhalation. Digital inhaler has built-in sensors that detect use of inhaler and measure inspiratory flow, according to the release and dose management. There are various types of digital dose inhaler available in the market such as metered dose inhaler (MDI) and dry powder inhaler (DPI). Out of which metered dose inhaler most widely used dose delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory disorders. 

Digital-Dose-Inhaler

COVID-19 Scenario Analysis:

To take care of infected population the demand for medical supplies is increasing. Respiratory support devices such as atomizer, life-support machine, oxygen generator, and monitor are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. With rise in number of COVID-19 cases worldwide, the need for medical supplies keeps on rising among, both from healthcare professionals and civil population for precautionary measures. Manufacturers of these products have a chance to capitalize this increased demand of medical supplies to ensure adequate and continuous supply of personal protective equipment in the market.

 The ongoing outbreak of COVID-19 pandemic impacted the medical device industry positively. It affect digital dose inhaler market. This increasing pandemic situation affect the supply chain and reduce the demand of digital dose inhaler devices which attributed to temporarily shutting down of industries and announcement of lockdown by government in various region  

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Globally, North America hold the largest market share and dominate overall digital dose inhaler market due to the increasing research and development activities, growing awareness regarding hi-tech respiratory devices, increasing incidence of respiratory disorders. However, the Asia Pacific is anticipated to expand market growth rate which attributed to increasing geriatric population, increases respiratory devices vertical, growing demand for advanced respiratory care devices, in addition, the presence of favourable government initiatives, such as “Make in India” campaign, which provides startup companies with subsidized land rates to launch their manufacturing units which help to expand the digital dose inhaler market in developing region. According to “WHO” report, in 2015, around 3 million deaths occur due to COPD across the globe. “WHO” also reported that more than 90% of the COPD deaths occurred in the developing countries. 

The factors such as the increasing geriatric population, growing respiratory disorders of both, severe and mild forms, increasing demand for these new generation inhalation devices, rising demand for cost-effective medications, growing awareness amongst the people about the benefits of generic drugs, etc., are expected to significantly drive the digital dose inhaler market. However, the factors that restrain the growth of market such as high cost of medication and devices, lack of awareness amongst the people about advanced treatment and available devices for asthma, and reduce the investment in R&D activities. The opportunities available for digital dose inhaler market such as, increasing investment in R&D activities, developing advancement in manufacturing devices for asthma and providing cost effective medication for patient. 

New Product launch to flourish the market:

Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications.

 In 2017, “Glenmark Pharmaceuticals Limited”, launched as India’s first Digital Dose Inhaler such as “Digihaler”, for asthma and pulmonary disease patients. This inhaler provides accurate digital dose counter along with low dose warning indicator to allow asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy,

In 2018, “Novartis”, has launched “Symbicort”. This inhaler used to control and prevent the symptoms of asthma in adults and children at least 6 years old and also used to control the symptoms of chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema

In 2019, Propeller Health has launched “Diskus®” This product is used to control and prevent symptoms like wheezing and shortness of breath caused by asthma and ongoing lung disease such as chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema.

In 2019, “Teva Pharmaceutical Industries Ltd”. announced that the U.S. Food and Drug Administration (FDA) has approved “ProAir Digihaler”  inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. ProAir Digihaler is used for the treatment or prevention of bronchospasm in patients aged four years and older with reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm (EIB) in patients aged four years and older.

Key benefits of the report:

  • This study presents the analytical depiction of the global digital dose inhaler market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global digital dose inhaler market share.
  • The current market is quantitatively analyzed to highlight the global digital dose inhaler market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed global digital dose inhaler market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the Digital Dose Inhaler Market research report:

  • Who are the leading market players active in digital dose inhaler market?
  • What are the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that will help in taking further strategic steps?

Digital Dose Inhaler Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Product
  • Metered Dose Inhaler (MDI)
  • Dry Powder Inhaler (DPI)
By Type
  • Branded Medication
  • Generic Medication
By Application
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Others
By End User
  • Medical Device Industry
  • Hospital
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Gecko Health Innovations, Inc., Opko Health, Inc., Cipla, Inc., AstraZeneca Plc, Glenmark Pharmaceuticals Ltd., AptarGroup Inc., Novartis AG, Propeller Health, GlaxoSmithKline Plc., Philips Respironics, Koninklijke Phillips N.V., Teva Pharmaceutical Industries Ltd.
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: DIGITAL DOSE INHALER MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Metered Dose Inhaler (MDI)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Dry Powder Inhaler (DPI)

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: DIGITAL DOSE INHALER MARKET, BY TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Type

    • 5.2. Branded Medication

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Generic Medication

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: DIGITAL DOSE INHALER MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Chronic Obstructive Pulmonary Disease (COPD)

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Asthma

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: DIGITAL DOSE INHALER MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Medical Device Industry

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Hospital

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

  • CHAPTER 8: DIGITAL DOSE INHALER MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Type

      • 8.2.4. Market Size and Forecast, By Application

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Digital Dose Inhaler Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Type
        • 8.2.7.3. Market Size and Forecast, By Application
        • 8.2.7.4. Market Size and Forecast, By End User
      • 8.2.8. Canada Digital Dose Inhaler Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Type
        • 8.2.8.3. Market Size and Forecast, By Application
        • 8.2.8.4. Market Size and Forecast, By End User
      • 8.2.9. Mexico Digital Dose Inhaler Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Type
        • 8.2.9.3. Market Size and Forecast, By Application
        • 8.2.9.4. Market Size and Forecast, By End User
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Type

      • 8.3.4. Market Size and Forecast, By Application

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Digital Dose Inhaler Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Type
        • 8.3.7.3. Market Size and Forecast, By Application
        • 8.3.7.4. Market Size and Forecast, By End User
      • 8.3.8. Germany Digital Dose Inhaler Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Type
        • 8.3.8.3. Market Size and Forecast, By Application
        • 8.3.8.4. Market Size and Forecast, By End User
      • 8.3.9. Italy Digital Dose Inhaler Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Type
        • 8.3.9.3. Market Size and Forecast, By Application
        • 8.3.9.4. Market Size and Forecast, By End User
      • 8.3.10. Spain Digital Dose Inhaler Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Type
        • 8.3.10.3. Market Size and Forecast, By Application
        • 8.3.10.4. Market Size and Forecast, By End User
      • 8.3.11. UK Digital Dose Inhaler Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Type
        • 8.3.11.3. Market Size and Forecast, By Application
        • 8.3.11.4. Market Size and Forecast, By End User
      • 8.3.12. Russia Digital Dose Inhaler Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Type
        • 8.3.12.3. Market Size and Forecast, By Application
        • 8.3.12.4. Market Size and Forecast, By End User
      • 8.3.13. Rest Of Europe Digital Dose Inhaler Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Type
        • 8.3.13.3. Market Size and Forecast, By Application
        • 8.3.13.4. Market Size and Forecast, By End User
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Type

      • 8.4.4. Market Size and Forecast, By Application

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Digital Dose Inhaler Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Type
        • 8.4.7.3. Market Size and Forecast, By Application
        • 8.4.7.4. Market Size and Forecast, By End User
      • 8.4.8. Japan Digital Dose Inhaler Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Type
        • 8.4.8.3. Market Size and Forecast, By Application
        • 8.4.8.4. Market Size and Forecast, By End User
      • 8.4.9. India Digital Dose Inhaler Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Type
        • 8.4.9.3. Market Size and Forecast, By Application
        • 8.4.9.4. Market Size and Forecast, By End User
      • 8.4.10. South Korea Digital Dose Inhaler Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Type
        • 8.4.10.3. Market Size and Forecast, By Application
        • 8.4.10.4. Market Size and Forecast, By End User
      • 8.4.11. Australia Digital Dose Inhaler Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Type
        • 8.4.11.3. Market Size and Forecast, By Application
        • 8.4.11.4. Market Size and Forecast, By End User
      • 8.4.12. Thailand Digital Dose Inhaler Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Type
        • 8.4.12.3. Market Size and Forecast, By Application
        • 8.4.12.4. Market Size and Forecast, By End User
      • 8.4.13. Malaysia Digital Dose Inhaler Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Type
        • 8.4.13.3. Market Size and Forecast, By Application
        • 8.4.13.4. Market Size and Forecast, By End User
      • 8.4.14. Indonesia Digital Dose Inhaler Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Type
        • 8.4.14.3. Market Size and Forecast, By Application
        • 8.4.14.4. Market Size and Forecast, By End User
      • 8.4.15. Rest of Asia Pacific Digital Dose Inhaler Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Type
        • 8.4.15.3. Market Size and Forecast, By Application
        • 8.4.15.4. Market Size and Forecast, By End User
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Type

      • 8.5.4. Market Size and Forecast, By Application

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Digital Dose Inhaler Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Type
        • 8.5.7.3. Market Size and Forecast, By Application
        • 8.5.7.4. Market Size and Forecast, By End User
      • 8.5.8. South Africa Digital Dose Inhaler Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Type
        • 8.5.8.3. Market Size and Forecast, By Application
        • 8.5.8.4. Market Size and Forecast, By End User
      • 8.5.9. Saudi Arabia Digital Dose Inhaler Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Type
        • 8.5.9.3. Market Size and Forecast, By Application
        • 8.5.9.4. Market Size and Forecast, By End User
      • 8.5.10. UAE Digital Dose Inhaler Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Type
        • 8.5.10.3. Market Size and Forecast, By Application
        • 8.5.10.4. Market Size and Forecast, By End User
      • 8.5.11. Argentina Digital Dose Inhaler Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Type
        • 8.5.11.3. Market Size and Forecast, By Application
        • 8.5.11.4. Market Size and Forecast, By End User
      • 8.5.12. Rest of LAMEA Digital Dose Inhaler Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Type
        • 8.5.12.3. Market Size and Forecast, By Application
        • 8.5.12.4. Market Size and Forecast, By End User
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Glenmark Pharmaceuticals Ltd.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Novartis AG

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Propeller Health

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. AstraZeneca Plc

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Philips Respironics

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Opko Health, Inc.

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Teva Pharmaceutical Industries Ltd.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Gecko Health Innovations, Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Koninklijke Phillips N.V.

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. GlaxoSmithKline Plc.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. AptarGroup Inc.

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

    • 10.12. Cipla, Inc.

      • 10.12.1. Company Overview

      • 10.12.2. Key Executives

      • 10.12.3. Company Snapshot

      • 10.12.4. Operating Business Segments

      • 10.12.5. Product Portfolio

      • 10.12.6. Business Performance

      • 10.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL DOSE INHALER MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL DIGITAL DOSE INHALER MARKET FOR METERED DOSE INHALER (MDI), BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL DIGITAL DOSE INHALER MARKET FOR DRY POWDER INHALER (DPI), BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL DIGITAL DOSE INHALER MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL DIGITAL DOSE INHALER MARKET FOR BRANDED MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL DIGITAL DOSE INHALER MARKET FOR GENERIC MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL DIGITAL DOSE INHALER MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL DIGITAL DOSE INHALER MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL DIGITAL DOSE INHALER MARKET FOR ASTHMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL DIGITAL DOSE INHALER MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL DIGITAL DOSE INHALER MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL DIGITAL DOSE INHALER MARKET FOR MEDICAL DEVICE INDUSTRY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL DIGITAL DOSE INHALER MARKET FOR HOSPITAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL DIGITAL DOSE INHALER MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA DIGITAL DOSE INHALER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. U.S. DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. U.S. DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. CANADA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE DIGITAL DOSE INHALER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. ITALY DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. ITALY DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. ITALY DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. ITALY DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. UK DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. UK DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. UK DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. UK DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. RUSSIA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC DIGITAL DOSE INHALER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. CHINA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. CHINA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. CHINA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. CHINA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 75. JAPAN DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. INDIA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 79. INDIA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH KOREA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. AUSTRALIA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 87. AUSTRALIA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. AUSTRALIA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. THAILAND DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 91. THAILAND DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. THAILAND DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. MALAYSIA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 95. MALAYSIA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 96. MALAYSIA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. INDONESIA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 99. INDONESIA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 100. INDONESIA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. REST OF ASIA PACIFIC DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 103. REST OF ASIA PACIFIC DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF ASIA PACIFIC DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. LAMEA DIGITAL DOSE INHALER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 107. LAMEA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 108. LAMEA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. BRAZIL DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 112. BRAZIL DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 113. BRAZIL DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. SOUTH AFRICA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 116. SOUTH AFRICA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 119. SAUDI ARABIA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 120. SAUDI ARABIA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 121. SAUDI ARABIA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 123. UAE DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 124. UAE DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 125. UAE DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 126. UAE DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 127. ARGENTINA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 128. ARGENTINA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 129. ARGENTINA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. REST OF LAMEA DIGITAL DOSE INHALER, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 132. REST OF LAMEA DIGITAL DOSE INHALER, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 133. REST OF LAMEA DIGITAL DOSE INHALER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA DIGITAL DOSE INHALER, BY END USER, 2022-2032 ($MILLION)
  • TABLE 135. GLENMARK PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 136. GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 137. GLENMARK PHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 138. GLENMARK PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 139. GLENMARK PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 141. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 142. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 143. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 144. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. PROPELLER HEALTH: KEY EXECUTIVES
  • TABLE 146. PROPELLER HEALTH: COMPANY SNAPSHOT
  • TABLE 147. PROPELLER HEALTH: OPERATING SEGMENTS
  • TABLE 148. PROPELLER HEALTH: PRODUCT PORTFOLIO
  • TABLE 149. PROPELLER HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 151. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 152. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 153. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 154. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. PHILIPS RESPIRONICS: KEY EXECUTIVES
  • TABLE 156. PHILIPS RESPIRONICS: COMPANY SNAPSHOT
  • TABLE 157. PHILIPS RESPIRONICS: OPERATING SEGMENTS
  • TABLE 158. PHILIPS RESPIRONICS: PRODUCT PORTFOLIO
  • TABLE 159. PHILIPS RESPIRONICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. OPKO HEALTH, INC.: KEY EXECUTIVES
  • TABLE 161. OPKO HEALTH, INC.: COMPANY SNAPSHOT
  • TABLE 162. OPKO HEALTH, INC.: OPERATING SEGMENTS
  • TABLE 163. OPKO HEALTH, INC.: PRODUCT PORTFOLIO
  • TABLE 164. OPKO HEALTH, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 165. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 166. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 167. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 168. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 169. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170. GECKO HEALTH INNOVATIONS, INC.: KEY EXECUTIVES
  • TABLE 171. GECKO HEALTH INNOVATIONS, INC.: COMPANY SNAPSHOT
  • TABLE 172. GECKO HEALTH INNOVATIONS, INC.: OPERATING SEGMENTS
  • TABLE 173. GECKO HEALTH INNOVATIONS, INC.: PRODUCT PORTFOLIO
  • TABLE 174. GECKO HEALTH INNOVATIONS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. KONINKLIJKE PHILLIPS N.V.: KEY EXECUTIVES
  • TABLE 176. KONINKLIJKE PHILLIPS N.V.: COMPANY SNAPSHOT
  • TABLE 177. KONINKLIJKE PHILLIPS N.V.: OPERATING SEGMENTS
  • TABLE 178. KONINKLIJKE PHILLIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 179. KONINKLIJKE PHILLIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 181. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 182. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 183. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 184. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. APTARGROUP INC.: KEY EXECUTIVES
  • TABLE 186. APTARGROUP INC.: COMPANY SNAPSHOT
  • TABLE 187. APTARGROUP INC.: OPERATING SEGMENTS
  • TABLE 188. APTARGROUP INC.: PRODUCT PORTFOLIO
  • TABLE 189. APTARGROUP INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 190. CIPLA, INC.: KEY EXECUTIVES
  • TABLE 191. CIPLA, INC.: COMPANY SNAPSHOT
  • TABLE 192. CIPLA, INC.: OPERATING SEGMENTS
  • TABLE 193. CIPLA, INC.: PRODUCT PORTFOLIO
  • TABLE 194. CIPLA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL DOSE INHALER MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DIGITAL DOSE INHALER MARKET
  • FIGURE 3. SEGMENTATION DIGITAL DOSE INHALER MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DIGITAL DOSE INHALER MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDIGITAL DOSE INHALER MARKET
  • FIGURE 11. DIGITAL DOSE INHALER MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. DIGITAL DOSE INHALER MARKET FOR METERED DOSE INHALER (MDI), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. DIGITAL DOSE INHALER MARKET FOR DRY POWDER INHALER (DPI), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. DIGITAL DOSE INHALER MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 15. DIGITAL DOSE INHALER MARKET FOR BRANDED MEDICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. DIGITAL DOSE INHALER MARKET FOR GENERIC MEDICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. DIGITAL DOSE INHALER MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 18. DIGITAL DOSE INHALER MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. DIGITAL DOSE INHALER MARKET FOR ASTHMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. DIGITAL DOSE INHALER MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. DIGITAL DOSE INHALER MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. DIGITAL DOSE INHALER MARKET FOR MEDICAL DEVICE INDUSTRY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. DIGITAL DOSE INHALER MARKET FOR HOSPITAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: DIGITAL DOSE INHALER MARKET
  • FIGURE 30. Top player positioning, 2022
  • FIGURE 31. GLENMARK PHARMACEUTICALS LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. GLENMARK PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. GLENMARK PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. PROPELLER HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. PROPELLER HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. PROPELLER HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. PHILIPS RESPIRONICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. PHILIPS RESPIRONICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. PHILIPS RESPIRONICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. OPKO HEALTH, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. OPKO HEALTH, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. OPKO HEALTH, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. GECKO HEALTH INNOVATIONS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. GECKO HEALTH INNOVATIONS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. GECKO HEALTH INNOVATIONS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. KONINKLIJKE PHILLIPS N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. KONINKLIJKE PHILLIPS N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. KONINKLIJKE PHILLIPS N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. APTARGROUP INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. APTARGROUP INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. APTARGROUP INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. CIPLA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. CIPLA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. CIPLA, INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Digital Dose Inhaler Market

Start reading.
This Report and over 68,418+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers